AIDXHealthcare · Medical Devices

AIDX Stock Forecast: 20/20 Biolabs, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$0.38

+11.47% on the day

The 1 Wall Street analysts covering 20/20 Biolabs, Inc. hold a median 12-month price target of $5 — +1219.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$4.5M

Ticker Nerd rank

3 / 100

Median analyst target

$5.00

Analysts covering

Revenue$731K+31.9% y/y

Operating income−$1.2M

Net income−$1.5M

Free cash flow−$613K

Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−7.6%

−34.7%

From high

−98.4%

From low

+11.5%

$24

Range since 19 Feb 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

AIDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 20/20 Biolabs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Value

Momentum

Growth

Accruals

Quality

Volatility

Issuance

Size (96): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 19 Feb 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $5.00Median $5.00High $5.00

The green dot is the last close — the median target sits +1219.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
11 May 2026	Maxim Group	Initiates	Buy	$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIDX appears on the weeks it earns a place.

Performance

AIDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

AIDX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

20/20 Biolabs, Inc. (AIDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.0×
Price / sales: 2.2×
Price / book: 2.6×
EV / EBITDA: −0.5×

Growth & margins

Revenue growth (YoY): 36.5%
Earnings growth (YoY): 31.9%
Gross margin: 41.7%
Operating margin: −170.3%
Net margin: −285.0%

Returns & dividend

Return on equity: −331.2%
Return on assets: −62.4%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

20/20 Biolabs, Inc. (AIDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

20/20 Biolabs, Inc. has a market value of $4.5M and an enterprise value of $2.1M.
Revenue in the twelve months to 30 June 2026: $2.0M. The latest quarter grew 36.5% year on year.
Net income over the same four quarters: −$5.8M, a −285.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$2.8M.
Shares outstanding: 12.3M.
Trailing P/E: −1.0×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
20/20 Biolabs, Inc. employs 4 people — $510K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

AIDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
AIDX20/20 Biolabs, Inc.	$4.5M	3
POASPhaos Technology Holdings (Cayman) Ltd.	$4.5M	2
VVOSVivos Therapeutics, Inc.	$5.0M	28
INBSIntelligent Bio Solutions, Inc.	$5.2M	15
ICCMIceCure Medical Ltd.	$3.9M	38
NVNOenVVeno Medical Corp.	$5.7M	36
BJDXBluejay Diagnostics, Inc.	$3.6M	17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 20/20 Biolabs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIDX news & analysis

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

GlobeNewsWire · 2 Oct 2026neutral

20/20 BioLabs, Inc. announced that President and CEO Jonathan Cohen and CFO Alan Bergman will participate in the Maxim Growth Summit 2026 at the Hard Rock Hotel New York on October 13 and 14, 2026, where management will hold one-on-one meetings with institutional investors.

Why it matters — AIDX watchers would care because the company's leadership will have direct engagement opportunities with institutional investors, raising the company's visibility in the investment community.

20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model

GlobeNewsWire · 29 Sept 2026positive

20/20 BioLabs announced it will host an investor webinar on October 7, 2026, in which President and CEO Jonathan Cohen will discuss the FDA Advisory Committee vote, the company's new OneTest franchise model, preliminary interest from laboratories across the United States, and new state funding for firefighter cancer screening. Registration for the webinar is now open.

Why it matters — The webinar gives AIDX watchers a direct forum for information on the FDA committee vote, the OneTest franchise rollout, laboratory interest, and state funding—key developments for the company's multi-cancer early detection business.

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

GlobeNewsWire · 28 Aug 2026neutral

20/20 BioLabs rescheduled its investor webinar to 2:00 p.m. Eastern Time on September 2, 2026. The webinar will discuss OneTest™ revenue and the company's expanding commercial opportunity.

Why it matters — An AIDX watcher would care because the webinar is set to provide an update on OneTest™ revenue and the company's expanding commercial opportunity.

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

GlobeNewsWire · 26 Aug 2026positive

20/20 BioLabs announced it will host an investor webinar on September 2, 2026, at 12:00 p.m. Eastern Time. CEO Jonathan Cohen is scheduled to discuss the company's strongest quarterly performance since the commercial launch of its multi-cancer early detection testing, takeaways from the Next Generation Dx Summit, and the path to broader commercial adoption of OneTest™.

Why it matters — AIDX watchers are given an official opportunity to hear directly from the CEO about OneTest revenue and the company's expanding commercial opportunity, which directly relates to its commercialization progress.

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

GlobeNewsWire · 17 Aug 2026positive

20/20 BioLabs reported its second quarter 2026 financial and operational results, highlighted by record quarterly OneTest™ revenue of $0.7 million, a 47% year-over-year increase. Gross profit rose 87% to $0.3 million with gross margin expanding to 41.7% from 30.5%, while cash stood at $4.5 million as of June 30, 2026 and all convertible note debt was eliminated during the quarter.

Why it matters — The results show the company's flagship multi-cancer early detection test reaching record quarterly revenue with improved margins and a stronger balance sheet, marking meaningful operational progress for AIDX watchers.

FAQ

Frequently asked questions about AIDX stock

What is the AIDX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering 20/20 Biolabs, Inc. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIDX stock a buy right now?

Of the 1 analysts covering 20/20 Biolabs, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 20/20 Biolabs, Inc. 3 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIDX?

As at 8 Oct 2026, 20/20 Biolabs, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will AIDX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1219.3% from the last close, and Ticker Nerd's factor model ranks 20/20 Biolabs, Inc. 3 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIDX stock forecast for 2030?

No analyst covering 20/20 Biolabs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

What does 20/20 Biolabs, Inc. do?

20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.

What is the latest news on AIDX?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026". 20/20 BioLabs, Inc. announced that President and CEO Jonathan Cohen and CFO Alan Bergman will participate in the Maxim Growth Summit 2026 at the Hard Rock Hotel New York on October 13 and 14, 2026, where management will hold one-on-one meetings with institutional investors.

Company

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company’s core offerings include the OneTest family, which covers multi-cancer early detection testing and longevity-related biomarker analysis. It also operates CLIAx, a clinical laboratory innovation platform that supports diagnostic development and testing workflows for emerging health technology companies. 20/20 Biolabs serves the healthcare diagnostics market with products and services designed to improve clinical utility through machine learning and real-world data. Based in Gaithersburg, Maryland, the company plays a role in expanding access to advanced laboratory testing and supporting broader adoption of precision diagnostics.

CEO Mr. Jonathan Cohen · 4 employees · United States · https://2020biolabs.com